Cannabidiol Treatment of Cognitive Dysfunction in Schizophrenia

Cannabinoid Receptor Antagonist Treatment of Cognitive Dysfunction in Schizophrenia

This study is a six-week, randomized, placebo-controlled, fixed dose trial comparing cannabidiol Vs. placebo added to a stable dose of antipsychotic medications in patients diagnosed with schizophrenia.

Inclusion Criteria:

• Schizophrenia or Schizoaffective disorder (DSM-IV SCID-confirmed),

Exclusion Criteria:

• Women who are pregnant, nursing or unwilling to use appropriate birth control measures during study participation.